Millennium Management LLC Acquires 523,571 Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Millennium Management LLC lifted its stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 357.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 670,065 shares of the company's stock after purchasing an additional 523,571 shares during the period. Millennium Management LLC owned 1.17% of Ginkgo Bioworks worth $6,580,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of the business. Coastal Bridge Advisors LLC increased its stake in Ginkgo Bioworks by 1,609.8% in the 4th quarter. Coastal Bridge Advisors LLC now owns 276,817 shares of the company's stock worth $2,718,000 after buying an additional 260,627 shares in the last quarter. Balyasny Asset Management L.P. increased its stake in Ginkgo Bioworks by 277.1% in the 4th quarter. Balyasny Asset Management L.P. now owns 80,743 shares of the company's stock worth $793,000 after buying an additional 59,334 shares in the last quarter. Bank of America Corp DE increased its stake in Ginkgo Bioworks by 780.6% in the 4th quarter. Bank of America Corp DE now owns 3,764,455 shares of the company's stock worth $36,967,000 after buying an additional 3,336,964 shares in the last quarter. BNP Paribas Financial Markets increased its stake in Ginkgo Bioworks by 80.6% in the 4th quarter. BNP Paribas Financial Markets now owns 285,111 shares of the company's stock worth $2,800,000 after buying an additional 127,249 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV purchased a new stake in Ginkgo Bioworks in the 4th quarter worth $116,000. Hedge funds and other institutional investors own 78.63% of the company's stock.

Ginkgo Bioworks Stock Down 4.0%

DNA stock traded down $0.29 during trading on Friday, reaching $6.96. The company's stock had a trading volume of 769,651 shares, compared to its average volume of 1,452,624. Ginkgo Bioworks Holdings, Inc. has a 1 year low of $5.00 and a 1 year high of $23.24. The company has a market capitalization of $407.38 million, a P/E ratio of -0.53 and a beta of 1.29. The company's fifty day moving average is $7.19 and its 200-day moving average is $9.02.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.35). Ginkgo Bioworks had a negative net margin of 298.78% and a negative return on equity of 58.54%. The company had revenue of $48.32 million for the quarter, compared to the consensus estimate of $38.70 million. Analysts anticipate that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current year.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.